PharmaEssentia Corporation (TPE:6446)
Taiwan
· Delayed Price · Currency is TWD 640.00
+10.00 (1.59%)
Feb 21, 2025, 1:30 PM CST
PharmaEssentia Revenue
PharmaEssentia had revenue of 2.71B TWD in the quarter ending September 30, 2024, with 107.72% growth. This brings the company's revenue in the last twelve months to 8.32B, up 93.47% year-over-year. In the year 2023, PharmaEssentia had annual revenue of 5.11B with 77.15% growth.
Revenue (ttm)
8.32B
Revenue Growth
+93.47%
P/S Ratio
25.44
Revenue / Employee
63.51M
Employees
131
Market Cap
213.05B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 5.11B | 2.22B | 77.15% |
| Dec 31, 2022 | 2.88B | 2.23B | 339.00% |
| Dec 31, 2021 | 656.51M | 99.25M | 17.81% |
| Dec 31, 2020 | 557.26M | 251.57M | 82.29% |
| Dec 31, 2019 | 305.69M | 279.46M | 1,065.16% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Caliway Biopharmaceuticals | 44.43M |
| Bora Pharmaceuticals Co., LTD. | 16.71B |
| Lotus Pharmaceutical | 17.59B |
| Lumosa Therapeutics | 37.82M |
| Oneness Biotech | 112.20M |
| Polaris Group | 75.65M |
| Pegavision | 7.06B |
| Center Laboratories | 1.57B |
PharmaEssentia News
- 5 days ago - ICC Arbitral Tribunal Rules in Favor of AOP Health in Arbitration Proceedings Pertaining to BESREMi® (Ropeginterferon alfa-2b) - Benzinga